Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 602

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 602
---
 maturities of three months or less, to be cash and cash equivalents. The Company evaluates the creditworthiness of these financial institutions in determining the risk associated with these balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash and cash equivalents. As of December 31, 2023 and 2022, the Company did not have any cash equivalents.

Concentration of Credit Risk

Financial instruments which subject the Company to a concentration of credit risk principally consist of cash and cash equivalents. The Company maintains its day-to-day operating cash balances with a major financial institution.

Fair Value Measurement

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on the assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

| ● | Level                                                                                      
 1: Unadjusted quoted prices in active markets for identical assets or liabilities.         |
| ● | Level                                                                                      
 2: Other than quoted prices included in Level 1 inputs that are observable for the asset   
 or liability, either directly or indirectly.                                               |
| ● | Level                                                                                      
 3: Unobservable inputs for the asset or liability used to measure fair value to the extent 
 that observable inputs are not available.                                                  |

The Company’s financial instruments include cash, accounts payable and notes payable. On December 31, 2023, the carrying amounts of cash, accounts payable and notes payable approximate fair values due to the short-term nature of these instruments.

| F-83 |

aegeria soft tissue llc

notes to the financial statements

December 31, 2023 and 2022

Research and Development

Research and development costs are expensed as incurred. Research and development costs include patent maintenance costs, clinical trial insurance, and consulting services. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.

Segment Reporting

Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operation decision maker in deciding how to allocate resources in assessing performance. The Company has determined that it has one operating segment.

Income Taxes

The Company was formed as a Delaware